Abstract

Purpose of reviewThis article will update and review the Miller Fisher variants (MFV) of Guillain-Barré syndrome (GBS) including the clinical presentation, diagnostic testing, and treatment.Recent findingsAlthough the diagnosis of GBS and MFV can be made on clinical grounds, cerebrospinal fluid (CSF) analysis, nerve conduction studies, imaging (e.g. ultrasound and MRI), and serologic testing can help to confirm the diagnosis. Some patients may need immunotherapy with either intravenous immunoglobulin (IVIg) or plasma exchange, and recent studies suggest that complement inhibition combined with IVIg could be of benefit, but further studies are needed to prove efficacy.SummaryGBS is characterized by an acute, ascending polyneuropathy, ataxia, areflexia, and CSF albuminocytologic dissociation. The MFV of GBS is associated with ophthalmoplegia. Clinicians should have high index of suspicion for MFV of GBS in patients with acute ophthalmoplegia in order to establish the diagnosis, perform appropriate evaluation, and start treatment.SDC video link:http://links.lww.com/COOP/A32.

Original languageEnglish (US)
Pages (from-to)462-466
Number of pages5
JournalCurrent Opinion in Ophthalmology
Volume30
Issue number6
DOIs
StatePublished - Nov 1 2019

Keywords

  • Guillain-Barré
  • Miller Fisher
  • anti-GQ1b
  • autoimmune

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Update: The Miller Fisher variants of Guillain-Barré syndrome'. Together they form a unique fingerprint.

Cite this